PPT-New Oral Anticoagulants: A Review

Babak Moini MD Veterans Affairs Hospital Noon Lecture S eries Acknowledgment Some of the slides were borrowed from Amanda Miller PharD Case1 68 male with hx of DM CHF and prior ischemic CVA admitted for new . Gonsalves MD Rajiv K Pruthi MBBS and Mrinal M Patnaik MBBS Abstract Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for decades However with the US Food and Drug Administration approval of new oral anticoagul Tran J Joseph L Young S McRae J Curnow H Nandurkar P Wood and C McLintock Haemostasis Thrombosis Unit The Alfred Hospital Haematology Department Melbourne University Melbourne Victoria Haematology Department St Vincents Hospital Haemophilia Treatmen Eliot Williams, MD PhD. Division of Hematology & Medical Oncology. Nothing to disclose. History of anticoagulant therapy. 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010. R2 Patcharee Seesongsom. R2 . Sirada. . Phojai. Advisor AJ . T. a. chawan. . J. iratiwanon. Scope. Overview. Introduction of NOACs. Rivaroxaban. ( . Xarelto. ). Dabigatran. ( . Pradaxa. ). Fawaz Altuwaijri. ACEM trainee. Introduction. Characteristics . of novel . anticoagulants. Laboratory Testing. Reversal in the bleeding patient. Introduction. Prevalence . atrial fibrillation. . 3.03 million in 2005. and major trauma. Dr. Tina . Biss. Consultant . Haematologist. Newcastle Hospitals NHS Foundation Trust. NTN Annual Trauma . Conference. 17. th. April 2015. Case history. 73 year old female . Anticoagulated. Assistant Professor. Department of Internal Medicine – Hospital Medicine Division. Medical Director – UNM Anticoagulation Clinic. Co-Director Antithrombotic Stewardship. Roadmap. Direct oral anticoagulants. Christopher Granger, . MD. Sean Pokorney, MD. . Disclosure (Dr. Granger). Research contracts: AstraZeneca, Daiichi, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, Medtronic Foundation, The Medicines Company, and Boehringer . What are Direct-Acting Oral Anticoagulants DOACsANSWERS by heartTreatments TestscontinuedAdhere to your medication regimen and do not abruptly stop taking your DOACs without 31rst talking with your d Lanae Fox, . PharmD. , BCPS. I have no financial disclosures to report. Objectives. Understand the relative benefits and limitations of oral anticoagulant options. Recognize strategies for optimal use of oral anticoagulants and minimize risk of bleeding with these agents. This presentation is based on the . December 2013. AHRQ WebM&M Spotlight Case. See the full article at . http://webmm.ahrq.gov. . CME credit is available. Commentary by: . Margaret . C. Fang. , MD, MPH, University of California, San Francisco. ?. That . major bleeding . occurs in about . 6.5% of patients on anticoagulants.. . That’s. . 1 patient in 15. . and commonly, GI Bleeding.. That . 1% . is . fatal bleeding . such as intracranial hemorrhage.. existing clots from growing larger. Although anticoagulants are sometimes called blood thinners , they do not actually thin the blood. The job of anticoagulants is to promote the smooth flow of bloo Geno J . Merli. , MD, MACP, FSVM, FHM. Professor Medicine & Surgery. Sidney Kimmel Medical College. Thomas Jefferson University Hospitals. Disclosures. Geno J . Merli. , MD. Research Grant BMS-Pfizer: ADIOS study completed 12/2019 Presented ACC Meeting 3/2019.